Stem Cell Sourcing
for Florida Clinics

There is a specific moment in every rapidly evolving regulatory landscape where the window between "this is technically permissible" and "this is verifiably compliant" becomes very narrow very fast. Florida just entered that window.

On July 1, 2025, Florida Senate Bill 1768 became effective, amending Florida Statutes § 458.3245 and § 459.0127 to authorize licensed allopathic and osteopathic physicians to administer stem cell therapies not yet approved by the FDA, specifically for orthopedics, wound care, and pain management.[1]

This is a major change in the operational landscape of regenerative medicine.

For a state that a 2021 survey identified as the leading geography for unlicensed stem cell interventions nationwide, codifying a legal pathway for non-FDA-approved therapies is a structural shift in how regenerative medicine is practiced, sourced, and enforced in the continental United States.[2]

The question posed at this stage is whether biologics sourcing infrastructure has matured enough to meet the documentation and cold chain standards the law now demands.

FDA Regulations Under 21 CFR Part 1271: What Still Applies in Florida

Before getting into what Florida now allows, the federal regulatory layer deserves precise attention, because the two frameworks are not fully harmonized and that tension carries real consequences for Florida stem cell clinics operating in this space.

The FDA regulates human cells, tissues, and cellular and tissue-based products under 21 CFR Part 1271, promulgated under the authority of the Public Health Service Act (42 U.S.C. § 264) and the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.).[3] Under this framework, a product qualifies as a "361 HCT/P," exempt from premarket approval, only if it satisfies four criteria simultaneously: minimally manipulated, intended for homologous use only, not combined with any other article except water, crystalloids, or a storage agent, and either carrying no systemic effect or used autologously.[4]

Products that fall outside any of those four criteria require a full Biologics License Application under Section 351 of the PHS Act before commercial distribution. The FDA's 2020 guidance on minimal manipulation and homologous use makes this framework explicit, and the agency has enforced it consistently through warning letters and injunctions against clinics and manufacturers distributing unapproved allogeneic products.[5]

Florida's SB 1768 creates a state-level authorization that runs parallel to this federal structure, but does not preempt it. Critically, the law does not protect manufacturers who ship products into Florida from out of state. When biologics travel in interstate commerce, federal FDA jurisdiction is intact regardless of what Florida law says.[6] State authorization at the legislative level does not neutralize federal enforcement authority, and the documented history of FDA injunctions against unapproved HCT/P manufacturers operating under assumed state protection makes that clear.

Florida SB 1768 Stem Cell Therapy Requirements for Physicians

The statute is detailed and the compliance obligations are specific. A summary of what Florida stem cell clinics are required to meet:

MSC Biology and Why Stem Cell Source Quality Determines Clinical Outcomes

The legal requirements are one dimension of this conversation. The biological reality of what you are sourcing is the other, and for clinicians who will stand behind these treatments in front of patients, the biology is what keeps you up at night.

Mesenchymal stem cells are not a homogenous commodity. A 2025 review in Frontiers in Bioengineering and Biotechnology describes the core challenge with precision: MSC therapeutic function varies with donor characteristics including age, sex, and health status; tissue source (bone marrow, adipose, umbilical cord); and culture conditions including media formulation and oxygen levels.[15] MSCs from older donors exhibit reduced proliferation and diminished secretion of regenerative factors. Umbilical cord-derived MSCs demonstrate enhanced proliferative capacity and lower immunogenicity compared to adult bone marrow sources, which is part of why perinatal tissue has become the preferred source for allogeneic applications.[16]

This biological variability carries direct clinical consequences. It contributed to the Phase III failure of Prochymal, an MSC product for graft-versus-host disease, where variable IDO activity across donor lots produced inconsistent clinical outcomes.[17] Lot-to-lot variation in a living cell product is simultaneously a regulatory problem, a clinical outcomes problem, and a liability problem. Rigorous manufacturing controls and transparent characterization data are the only available tools to manage it.

On December 18, 2024, the FDA approved Ryoncil (remestemcel-L from Mesoblast Corporation), the first allogeneic MSC therapy approved for commercial use in the United States.

In orthopedic research specifically, a March 2024 meta-analysis in the Journal of Orthopaedic Surgery and Research covering 507 patients with knee osteoarthritis found that intra-articular injections of umbilical cord-derived MSCs produced statistically significant improvements in pain and function compared to placebo or hyaluronic acid, with no serious adverse events reported.[19]

Stem Cell Supplier Documentation Requirements Under Florida Law

Florida stem cell clinics building or revisiting their procurement protocols under SB 1768 should expect clear answers to all of the following from any supplier they work with:

FDA Enforcement vs. Florida SB 1768: Understanding the Compliance Risk

Legal observers have noted that the Florida law and federal law are structurally at odds in ways the FDA will eventually have to address.[21] Florida's population size and median age make it a substantial market, and if the agency's enforcement posture does not adapt, the gap between what state law permits and what federal law requires will widen as more states follow Florida's lead. Utah passed similar legislation in 2024, and legislative momentum in this direction continues to build.[22]

Federal enforcement authority over products that do not meet the 361 HCT/P criteria remains active and has not diminished under state-level authorization. The FDA's Center for Biologics Evaluation and Research has enforced consistently and specifically against exosomes, umbilical cord blood, Wharton's jelly, and amniotic tissue products marketed for cellular or cell-dependent indications without approval.[23] The agency's publicly stated posture has not shifted in response to SB 1768.

The physician who structures their stem cell sourcing around a supply chain that is simultaneously SB 1768-compliant and aligned with federal CGTP standards occupies the strongest defensible position regardless of how the federal-state tension ultimately resolves.